Rheumatoid Arthritis – Prognosis, Predictors and Outcome 2018
DOI: 10.1136/annrheumdis-2018-eular.3434
|View full text |Cite
|
Sign up to set email alerts
|

AB0228 Increase in global dna methylation at 3 months of methotrexate use is not associated to response in early ra patients

Abstract: BackgroundMethotrexate (MTX) is a first-line therapy in early Rheumatoid Arthritis (eRA). Still, up to 40% of treated patients do not adequately respond to MTX. MTX interferes with the folate cycle, where it indirectly inhibits the global DNA methylation donor S-adenosylmethionine (SAM). Thus, we hypothesised that global DNA methylation changes during MTX use are associated with treatment response.ObjectivesTo examine whether there is a change in global DNA methylation (Δ%Meth) upon MTX use and if this change … Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles